CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into an agreement with Biogen Idec under which GNS will use its proprietary REFS(TM) software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project. Financial terms of the agreement were not disclosed.
GNS employs massively parallel supercomputers to probe vast amounts of raw human biological data to discover new insights into the biological causes of human disease, and new opportunities for diagnosis and treatment. Under this agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation) platform to transform genetic, genomic, and clinical data provided by Biogen Idec to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly.
"Our proprietary technology is capable of taking raw 'omic' data and running billions of calculations in a short period of time to find potential biomarkers and promising drug targets that could lead to more effective patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed of our REFS(TM) technology and the potential it offers to the Biogen Idec drug development program that forged our partnership."
Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that
systematically turns multiple layers of biologically relevant data into an
unprecedented view of human biology and disease as a "whole." REFS(TM)
begins with raw biological data (genetic, genomic, epigenetic, proteomic,
metabolomic and environmental) and rapidly performs billions upon billions
of calculations to determine how the molecules interact with one another in
the complete system (Reverse Engineering). These computer-assembled models
are then querie
|SOURCE Gene Network Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved